Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
Shaji Kumar(Mayo Clinic in Arizona), Sherif Louis(Ontario Genomics)
Cited by 8
Related Papers
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
|Mayo Clinic Proceedings|2009|625
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
|Haematologica|2019|36